

ANTICOAGULATION MAJOR BLEEDING RISK SCORE IN ATRIAL FIBRILLATION

HYPERTENSION

Uncontrolled >160 mmHg Systolic

+1

RENAL DISEASE

Dialysis / Transplant / Cr > 200 μ mol/L

+1

LIVER DISEASE

Cirrhosis -or-

Bilirubin >2x normal with AST/ALP/AP >3x normal

+1

STROKE HISTORY

+1

PRIOR MAJOR BLEEDING OR PREDISPOSITION TO BLEEDING

+1

LABILE INR

Unstable / High INR's

Time in therapeutic range <60%

+1

MEDICATION PREDISPOSING TO BLEEDING

I.E. Aspirin / Clopidogrel / NSAIDSS

+1

AGE > 65

+1

ALCOHOL USE

\geq 8 DRINKS/WEEK

+1

RISK- BENEFIT ANALYSIS

Compare Major Bleeding risk to Stroke risk (CHA₂D-VAS₂) to assist in determining Risk-Benefit of Anticoagulation

MAJOR BLEEDING RISK

SCORE

% RISK - YEAR

PATIENT-YEAR



0

0.9%

1/100

1

3.4%

1/100

2

4.1%

2/100

3

5.8%

3.72/100

4

8.9%

8.7/100

5

9.1%

12.5/100

6

>10%

>12.5/100

RISK- BENEFIT ANALYSIS - QUICK GUIDE

SCORE 0-1

LOW RISK MAJOR BLEEDING

0.9-3.4%

\sim 1/100

Patient-Years

CONSIDER ANTICOAGULATION

SCORE 2

MODERATE RISK MAJOR BLEEDING

4.1%

\sim 2/100

Patient-Years

CONSIDER ANTICOAGULATION

SCORE 3+

HIGH RISK MAJOR BLEEDING

5.8-10 \pm 0%

\sim 4/100

Patient-Years

CONSIDER ALTERNATIVES TO ANTICOAGULATION